Compound polysaccharide of tremella, agaricus bisporus and bolete as well as preparation method and application of compound polysaccharide
By preparing a compound polysaccharide from Tremella fuciformis, Agaricus bisporus, and Boletus edulis, the problem of insignificant therapeutic effects on atherosclerosis in existing technologies has been solved, enabling targeted treatment of atherosclerosis, reducing serum lipids, improving lipid metabolism and intestinal flora imbalance, and providing a new treatment approach.
Patent Information
- Application Number
- CN202411209097.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-30
AI Technical Summary
There is a lack of effective and safe methods for treating atherosclerosis in the current technology. The therapeutic effect of tremella is not significant. There are no studies on the use of button mushrooms and boletus to improve atherosclerosis. Existing statin drugs have adverse reactions.
Using Tremella fuciformis, Agaricus bisporus, and Boletus edulis as raw materials, a compound polysaccharide was prepared by water extraction and alcohol precipitation. It is used to prevent and treat atherosclerosis, reduce serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol, alleviate intestinal flora imbalance, and improve lipid metabolism disorders.
Compound polysaccharides can reduce the levels of TC, TG, and LDL-C in serum, decrease the accumulation of lipid droplets in adipose tissue, improve lipid metabolism in ApoE-/- atherosclerotic mice, alleviate organ damage, and reduce the levels of atherosclerosis-related serum metabolites, providing a new therapeutic approach.
Smart Images

Figure CN118930679A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of natural drug development, and in particular to a compound polysaccharide of tremella, Agaricus bisporus and boletus, and a preparation method and application thereof. Background Art
[0002] Atherosclerosis is an important pathological basis for chronic inflammatory vascular diseases and various cardiovascular diseases caused by calcification of fibrous tissue and lipid accumulation. Atherosclerosis can lead to a series of diseases, such as ischemic stroke, heart disease and peripheral vascular disease. In 2020, the World Health Organization reported that cardiovascular disease (ischemic heart disease, stroke) is one of the three leading causes of death in the world. In the past 20 years, atherosclerosis remains the leading cause of cardiovascular disease morbidity and mortality worldwide, bringing huge economic burdens to patients and their families.
[0003] The commonly used drugs for clinical treatment of atherosclerosis are rosuvastatin or atorvastatin. Although the patient's condition can be effectively treated by these two drugs to a certain extent, up to one-third of patients still cannot get effective treatment for atherosclerosis. In addition, the use of statins can also cause adverse reactions such as liver damage, indigestion, and muscle pain. There is currently no effective and safe method to treat atherosclerosis.
[0004] Tremella is a traditional medicinal fungus with rich pharmacological activities. Existing Tremella-related inventions are not targeted at the treatment of atherosclerosis, and the treatment effect is minimal and the mechanism of action is unclear. There is no research report in the prior art on using Agaricus bisporus or Boletus as raw materials or auxiliary materials to improve atherosclerosis. Based on this, the present invention specifically proposes a compound polysaccharide of Tremella fuciformis, Agaricus bisporus and Boletus edulis, which is applied to the clinical treatment of atherosclerosis. Summary of the invention
[0005] The purpose of the present invention is to provide a compound polysaccharide of Tremella fuciformis, Agaricus bisporus and Boletus edulis and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art. The present invention uses Tremella fuciformis, Agaricus bisporus and Boletus edulis as raw materials and adopts a "water extraction and alcohol precipitation" method to obtain the compound polysaccharide, which has significant effects and conversion potential in preventing and treating atherosclerosis, and provides a new idea for the clinical treatment of atherosclerosis.
[0006] To achieve the above object, the present invention provides the following solutions:
[0007] The invention provides a compound polysaccharide. The compound polysaccharide is prepared by using tremella, Agaricus bisporus and boletus as raw materials through water extraction and alcohol precipitation. The weight ratio of tremella, Agaricus bisporus and boletus is (1-5): (1-3): (1-3).
[0008] Furthermore, the weight ratio of Tremella fuciformis, Agaricus bisporus and Boletus edulis is 3:2:2.
[0009] The present invention also provides a method for preparing the compound polysaccharide, comprising the following steps:
[0010] Washing, drying and crushing Tremella fuciformis, Agaricus bisporus and Boletus edulis respectively to obtain Tremella fuciformis powder, Agaricus bisporus powder and Boletus edulis powder;
[0011] Mixing Tremella powder, Agaricus bisporus powder and Boletus powder according to a prescribed weight ratio;
[0012] Take the mixed powder, add deionized water, extract twice, combine the extracts, and concentrate under reduced pressure to obtain a concentrate;
[0013] The concentrated solution is dialyzed, ethanol is added after the dialysis, and the precipitate is collected by centrifugation. The precipitate is the compound polysaccharide.
[0014] Furthermore, the volume ratio of the mixed powder to the deionized water is 1:30.
[0015] Furthermore, the extraction is carried out at 80°C.
[0016] Furthermore, the dialysis is performed by placing the precipitate under 3500Da conditions and dialyzing it at 4°C for 72 hours.
[0017] Furthermore, the volume concentration of the ethanol is 95%; the volume ratio of the concentrated liquid to the ethanol is 1:5.3.
[0018] The present invention also provides the use of the compound polysaccharide in preparing a drug for preventing or treating atherosclerosis.
[0019] Furthermore, the compound polysaccharide prevents and / or treats atherosclerosis by reducing fat accumulation, lowering the levels of triglycerides, total cholesterol and low-density lipoprotein cholesterol in serum, alleviating intestinal flora disorders, alleviating lipid metabolism disorders or reducing the levels of serum metabolites related to atherosclerosis.
[0020] The present invention also provides a medicine for preventing and treating atherosclerosis, comprising the compound polysaccharide.
[0021] The present invention discloses the following technical effects:
[0022] The formula of the present invention uses three kinds of edible fungi, and through careful processing and preparation, the optimal therapeutic effect of the compound polysaccharide is exerted to treat atherosclerosis in a targeted manner. The experimental verification shows that the compound polysaccharide prepared by the present invention can improve ApoE by reducing the content of TC, TG and LDL-C in serum. - / - Lipid metabolism function in atherosclerotic mice; Relieve ApoE - / -Organ damage in mice with atherosclerosis; reducing lipid droplet accumulation and cavitation in adipose tissue; improving the body's lipid metabolism capacity by reducing the proportion of white fat and increasing the proportion of brown fat; improving ApoE - / - The intestinal flora of atherosclerotic mice is disturbed, and the level of serum metabolites related to atherosclerosis can be reduced. And the effect is better than that of a single polysaccharide. It can be seen that the present invention provides a new idea for the clinical treatment of atherosclerosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0024] # indicates p < 0.05 compared with the normal diet blank group, ## indicates p < 0.01 compared with the normal diet blank group, ### indicates p < 0.001 compared with the normal diet blank group; * indicates p < 0.05 compared with the high-fat diet model group, ** indicates p < 0.01 compared with the high-fat diet model group, *** indicates p < 0.001 compared with the high-fat diet model group; ns indicates no statistically significant difference.
[0025] Figure 1 Figure 2 is the weight change of mice in each group;
[0026] Figure 2 The Oil Red O staining images of the aorta of mice in each group; NCD: normal diet blank group, HFD: high-fat diet model group, HFD+TF: Tremella fuciformis alone administration group, HFD+AB: Agaricus bisporus alone administration group, HFD+BE: Boletus alone administration group, HFD+CCP (3:2:2): compound polysaccharide administration group;
[0027] Figure 3 H&E staining images of adipose tissues of mice in each group; iWAT: inguinal white adipose tissue, eWAT: epididymal white adipose tissue, pWAT: perirenal white adipose tissue, BAT: brown adipose tissue;
[0028] Figure 4 Statistical graphs of adipose tissue index of mice in each group; A: inguinal white adipose tissue index; B: epididymal white adipose tissue index; C: perirenal white adipose tissue index; D: brown adipose tissue index;
[0029] Figure 5 The statistical graphs are the contents of triglyceride (A), total cholesterol (B) and low-density lipoprotein cholesterol (C) in the serum of mice in each group;
[0030] Figure 6 The statistical graphs of liver (A), heart (B), pancreas (C), spleen (D), thymus (E) and kidney (F) indexes of mice in each group;
[0031] Figure 7 Statistical chart of the number of intestinal flora species in each group of mice;
[0032] Figure 8 This is the number of species of intestinal flora in each group of mice;
[0033] Fig. 9 Statistical diagram of differential metabolites in each group of mice;
[0034] Fig.10 Statistical graph of metabolite changes in each group of mice;
[0035] Fig.11 Pathway enrichment statistics for each group of mice. DETAILED DESCRIPTION
[0036] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0037] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0038] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0039] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0040] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0041] Example 1
[0042] 1. Preparation of compound polysaccharides and single polysaccharides
[0043] Preparation of compound polysaccharide:
[0044] Cleaning and physical crushing: The three edible fungi, namely, Tremella fuciformis, Agaricus bisporus and Boletus, are cleaned and dried respectively, and then the Tremella fuciformis, Agaricus bisporus and Boletus with a diameter of more than 1 cm are cut into blocks or slices with a diameter of about 1 cm. The three edible fungi are crushed separately and passed through a 100-mesh sieve.
[0045] Compound prescription: Mix three kinds of edible fungus powders according to the weight ratio of 24 parts of Tremella fuciformis, 16 parts of Agaricus bisporus and 16 parts of Boletus edulis (3:2:2);
[0046] Polysaccharide extraction: Take 200g of the mixed powder, add 6000mL of deionized water, extract at 80℃ for 4h, twice, combine the extracts to obtain a water extract, and concentrate the extract under reduced pressure to about 150mL.
[0047] Dialysis: The concentrated solution was placed in a 3500Da dialysis bag and dialyzed in a chromatography cabinet at 4°C for 72 h.
[0048] Alcohol precipitation: add 95% ethanol in a volume concentration of 1:5.3, let stand overnight at 4°C, then centrifuge at 5000r / min for 10min, collect the precipitate, and the precipitate is the compound polysaccharide.
[0049] Preparation of individual polysaccharides:
[0050] The preparation of individual polysaccharides of Tremella fuciformis, Agaricus bisporus and Boletus edulis was the same as the above operation, except that the compound compatibility was not performed. After washing and physical crushing, the three edible fungi were subjected to subsequent operations such as polysaccharide extraction.
[0051] 2. Modeling and grouping
[0052] 8-week-old male ApoE - / - Thirty-six mice were randomly divided into 6 groups: normal diet blank group (NCD), high-fat diet model group (HFD), Tremella fuciformis alone group (HFD+TF), Agaricus bisporus alone group (HFD+AB), Boletus alone group (HFD+BE), compound polysaccharide group (HFD+CCP (3:2:2)). The model was established for 70 days (weeks 1-10) and the drug was administered for 28 days (weeks 11-14).
[0053] ApoE - / -During the high-fat diet modeling period (weeks 1-10), high-fat feed and ordinary feed were checked at 9 am every day, and the insufficient feed was supplemented or replaced with oxidized feed in time. During the treatment period (weeks 11-14), NCD and HFD were gavaged with 5 mL / kg normal saline at 9 am every day; HFD+TF, HFD+AB, HFD+BE and HFD+CCP (3:2:2) groups were gavaged with the corresponding polysaccharides, and the dosage was 50 mg / kg. The administration was continued for 28 days. The weight of the mice was weighed and recorded daily.
[0054] 3. Compound polysaccharide improves ApoE - / - Body weight changes in mice with atherosclerosis
[0055] Obesity and weight gain are important characteristics of atherosclerosis caused by a long-term high-fat diet. Figure 1 As shown. From the beginning of the experiment (week 6) to the end of modeling (week 10), the weight of mice on HFD was significantly higher than that of mice on NCD. After the end of administration (week 14), the weight of atherosclerotic mice on HFD+TF, HFD+AB, HFD+BE and HFD+CCP (3:2:2) decreased significantly. This shows that compound polysaccharides can improve ApoE - / - Body weight changes in mice with atherosclerosis.
[0056] 4. Compound polysaccharide relieves ApoE - / - Atherosclerotic lesions in the aorta of atherosclerotic mice
[0057] Aortic lipid deposition is the main cause of atherosclerosis. After the administration, the mice were dissected and the aorta was placed in 4% paraformaldehyde tissue fixative for preservation. OCT embedding, frozen sectioning, staining and preparation of tissue sections were performed, and histological analysis was performed by Oil Red O staining. The results are as follows Figure 2 As shown in the figure, the relative staining area of Oil Red O in HFD mice was significantly higher than that in NCD mice. Compared with HFD, the relative staining area of HFD+TF, HFD+AB, HFD+BE and HFD+CCP (3:2:2) was significantly reduced, and the relative staining area of Oil Red O in the HFD+CCP (3:2:2) group of mice was less than that in HFD+TF, HFD+AB and HFD+BE. This shows that the compound polysaccharide can more effectively reduce lipid accumulation in the aorta and alleviate ApoE - / - Atherosclerotic lesions in the mouse aorta.
[0058] 5. Compound polysaccharide relieves ApoE - / - Lipid droplet accumulation and fat vacuolization in adipose tissue of atherosclerotic mice
[0059] Long-term high-fat diet can lead to the appearance of a large number of fat vacuoles in the adipose tissue of mice, a significant increase in the number of lipid droplets, and a high degree of fat infiltration, which can lead to lipid metabolism disorders. Figure 3 As shown: Compared with HFD, HFD+TF, HFD+AB, HFD+BE and HFD+CCP (3:2:2) had fewer fat vacuoles, fewer lipid droplets and smaller volumes, and the compound polysaccharide group had better effects, indicating that the compound can better reduce lipid accumulation in adipose tissue and reduce lipid infiltration. This further proves that the compound polysaccharide has a better lipid-lowering effect.
[0060] 6. Compound polysaccharide improves ApoE - / - Lipid metabolism in mice with atherosclerosis
[0061] After the administration, the mice were dissected, and the inguinal white adipose tissue (iWAT), epididymal white fat (eWAT), perirenal white adipose tissue (pWAT), and brown adipose tissue (BAT) of the mice were taken. The remaining blood on the surface was absorbed with absorbent paper and then weighed immediately, the data was recorded, and finally the fat index was calculated.
[0062] Fat index (%) = fat weight (g) / mouse weight before sacrifice (g) × 100
[0063] A high-fat diet can cause ApoE - / - The WAT index of mice increased and the BAT index decreased, which slowed down the normal lipid metabolism of mice and caused fat accumulation. Figure 4 As shown, compared with HFD, the WAT index of HFD+TF, HFD+AB, HFD+BE and HFD+CCP (3:2:2) was downregulated and the BAT index was upregulated, and the eWAT index of HFD+CCP (3:2:2) was downregulated and the BAT index was upregulated, indicating that the compound polysaccharide can effectively alleviate lipid metabolism disorders.
[0064] 7. Compound polysaccharide improves ApoE - / - Serum lipid metabolism function in mice with atherosclerosis
[0065] After the administration, blood was collected from the tail tip of the mouse, placed in a centrifuge, and centrifuged at 2500rpm for 15 minutes. The supernatant was serum. Dyslipidemia is an important cause of atherosclerosis. The levels of TG, TC, and LDL-C in serum can reflect the body's lipid metabolism to a certain extent and are important indicators for monitoring changes in blood lipids. Studies have shown that hyperlipidemia can lead to increased levels of TC, TG, and LDL-C.
[0066] The TG level was determined according to the instructions of the A110-1-1 triglyceride test kit of Nanjing Jiancheng Bioengineering Institute. The principle is the glycerol phosphate oxidase-peroxidase activator coupling method. Sample processing: dilute the serum ten times with physiological saline; add the corresponding samples or standards to the 96-well plate according to Table 1; the serum TG content (mmol / L) is determined as follows.
[0067]
[0068] Table 1 TG level measurement - 96-well plate sample loading reference table
[0069]
[0070] TC level was determined according to the instructions of the A111-1-1 total cholesterol test kit of Nanjing Jiancheng Bioengineering Institute. The principle is cholesterol oxidase-peroxidase coupling method. Sample processing: serum was diluted ten times with physiological saline; reference
[0071] Table 2 Corresponding samples or standards were added to a 96-well plate; serum TC content (mmol / L) was determined as follows.
[0072]
[0073] Table 2TC level measurement - 96-well plate sample loading reference table
[0074]
[0075] The LDL-C level was determined according to the instructions of the A113-1-1 total cholesterol test kit of Nanjing Jiancheng Bioengineering Institute. The principle is the microplate method. Sample processing: dilute the serum ten times with physiological saline; add the corresponding sample or standard to the 96-well plate according to Table 3; the serum LDL-C content (mmol / L) is determined as follows.
[0076]
[0077] Table 3 LDL-C level measurement - 96-well plate loading reference table
[0078]
[0079] ApoE in each group - / - The results of the effects on TC, TG and LDL-C levels in mouse serum are as follows Figure 5As shown. Compared with NCD, the levels of LDL-C, TC and TG in the serum of HFD mice were significantly increased (p<0.001). Compared with the results of HFD, the concentrations of TC, TG and LDL-C in the serum of HFD+TF, HFD+AB, HFD+BE and HFD+CCP (3:2:2) were all reduced, and the reduction effect of HFD+CCP (3:2:2) was better, indicating that the compound polysaccharide has a better effect.
[0080] 8. Compound polysaccharide relieves ApoE - / - Damage to major organs in atherosclerotic mice
[0081] The organ index is an important indicator of the health of the main organs of mice. After the administration, the heart, liver, spleen, kidney, thymus and pancreas of the mice were dissected and weighed. The remaining blood on the surface was blotted with absorbent paper and then weighed immediately. The data was recorded and the organ index was calculated.
[0082] Organ index (%) = organ weight (g) / mouse weight before sacrifice (g) × 100
[0083] like Figure 6 As shown, the high-fat diet caused an increase in the heart index (Heart Index), spleen index (Spleen Index), pancreas index (pancreas Index), kidney index (Kidney Index), liver index (LiverIndex) and a decrease in the thymus index (Thymus Index) of mice on HFD. Compared with the results of HFD, the pancreatic index of HFD+BE was not downregulated, and the thymus index of mice on HFD+AB was not upregulated. Compared with the results of HFD, the heart index, spleen index, kidney index and liver index of mice on HFD+TF, HFD+AB, HFD+BE and HFD+CCP (3:2:2) were downregulated. Compared with the results of HFD, the thymus index of mice on HFD+TF and HFD+CCP (3:2:2) was upregulated and the pancreatic index was downregulated. This shows that compound polysaccharides can better improve ApoE - / - Damage to major organs in atherosclerotic mice.
[0084] 9. Effect of compound polysaccharide on ApoE - / - Effect of intestinal flora on atherosclerosis in mice
[0085] The intestinal microbiota is the largest and most complex microbial community in the human body and plays a vital role in the occurrence and development of atherosclerosis. - / - The intestinal flora of mice with atherosclerosis is disordered and the number of flora decreases. By comparing the relative abundance distribution of differential microorganisms and genus levels in each group of mice, we can understand the effect of compound polysaccharides on the intestinal flora of mice.
[0086] Table 4 Primer sequences for V3-V4 variable regions
[0087]
[0088] Table 5 PCR reaction program
[0089]
[0090] After the administration, the cecal contents of HFD+CCP (3:2:2) mice were dissected and the genomic DNA of the samples was extracted using the OMEGAMag-bind soilDNAkit kit, and the purity and concentration of the DNA were tested. According to the selection of the sequencing region, the selected V3-V4 variable region was PCR amplified using specific primers with barcodes and high-fidelity DNA polymerase. The genomic DNA of the intestinal flora content was used as a PCR template, and specific primers with barcodes were selected according to the sequencing region (see Table 4), and 30 PCR reaction cycles were performed. The PCR reaction system was 30 μL, including 15 μL of Phusion Master Mix (2x), 3 μL of Primer (2 μM) (6 μM), 10 μL of gDNA (1 ng / μL) (5-10 ng), and 2 μL of H2O. The PCR cycle was 98℃, 10 sec; 50℃, 30 sec; 72℃, 30 sec, and the pre-denaturation condition was 98℃ 1 min (see Table 5). The PCR product was detected by 2% agarose gel electrophoresis, and the target fragment was cut and recovered by gel excision, wherein the Quant-iT PicoGreen dsDNA Assay Kit was used for gel recovery. Referring to the preliminary quantitative results of electrophoresis, the PCR amplification recovery product was detected and quantified by Microplate reader (dereplication) BioTek, FLx800 fluorescence quantitative system, wherein the corresponding proportion was mixed according to the sequencing amount requirements of each sample. The library was constructed using Illumina's TruSeq Nano DNA LT Library Prep Kit. The constructed library was quality inspected by Agilent Bioanalyzer2100 and Promega QuantiFluor, and the library was sequenced after passing the quality inspection. After obtaining the original sequencing data, the sequencing data quality was evaluated, and ASV / OUT was clustered and annotated. According to the results of ASVs cluster analysis and research needs, the venn diagram of NCD, HFD, and CCP (3:2:2) was drawn; according to the species annotation results, the top 30 species with the maximum abundance at the genus level of NCD, HFD, and HFD+CCP (3:2:2) were selected, and the species relative abundance column cumulative diagram was drawn using the Ouyi Cloud platform.
[0091] like Figure 7 As shown in Figure 2, the number of bacterial flora in the CCP (3:2:2) group mice was increased compared with the HFD group. Figure 8As shown, the populations of g_Dubosiella and f_Atopobiaceae|g_uncultured in mice on HFD decreased, and the populations of g_Dubosiella and f_Atopobiaceae|g_uncultured in mice in the CCP (3:2:2) group increased compared with the HFD group. The number of f_Lachnospiraceae|g_uncultured in mice on HFD decreased, and the number of f_Lachnospiraceae|g_uncultured in mice in the CCP (3:2:2) group increased compared with the HFD group. This indicates that the administration of compound polysaccharides alleviated the intestinal flora disorder in mice with atherosclerosis.
[0092] 10. Effect of compound polysaccharide on ApoE - / - Effects of atherosclerosis on body metabolism in mice
[0093] After the administration, the serum of mice was collected (the method was the same as that of "7. Compound polysaccharide improves ApoE - / - Serum lipid metabolism function in atherosclerotic mice”), the main steps of determining body metabolites include: sample preparation, QC preparation, sample LC-MS / MS mass spectrometry analysis, and data analysis.
[0094] Metabolite extraction: After HFD+CCP (3:2:2) mouse serum samples were slowly thawed at 4°C, appropriate amount of samples were added to pre-cooled methanol / acetonitrile / water solution (2:2:1, v / v), vortexed, sonicated at low temperature for 30 min, left at -20°C for 10 min, centrifuged at 14000g for 20 min at 4°C, the supernatant was vacuum dried, and 100 μL of acetonitrile aqueous solution (acetonitrile: water = 1:1, v / v) was added for re-dissolution during mass spectrometry analysis, vortexed, centrifuged at 14000g for 15 min at 4°C, and the supernatant was sampled for analysis. Then it was analyzed by chromatography-mass spectrometry.
[0095] Chromatographic conditions: The samples were separated using an Agilent 1290 Infinity LC ultra-high performance liquid chromatography system (UHPLC) HILIC column; column temperature 25°C; flow rate 0.5 mL / min; injection volume 2 μL; mobile phase composition A: water + 25 mM ammonium acetate + 25 mM ammonia, B: acetonitrile; gradient elution program as follows: 0-0.5 min, 95% B; 0.5-7 min, B linearly changed from 95% to 65%; 7-8 min, B linearly changed from 65% to 40%; 8-9 min, B maintained at 40%; 9-9.1 min, B linearly changed from 40% to 95%; 9.1-12 min, B maintained at 95%; the samples were placed in an automatic sampler at 4°C during the entire analysis process. To avoid the influence of fluctuations in instrument detection signals, samples were analyzed continuously in random order. QC samples were inserted into the sample queue to monitor and evaluate the stability of the system and the reliability of experimental data.
[0096] Mass spectrometry conditions: The primary and secondary spectra of the samples were collected using an AB Triple TOF 6600 mass spectrometer. After separation using an Agilent 1290 Infinity LC ultra-high performance liquid chromatography system (UHPLC), the samples were analyzed by mass spectrometry using a Triple TOF 6600 mass spectrometer (AB SCIEX), using electrospray ionization (ESI) positive and negative ion modes for detection. The ESI source setting parameters are as follows: nebulizer gas auxiliary heating gas 1 (Gas1): 60, auxiliary heating gas 2 (Gas2): 60, curtain gas (CUR): 30psi, ion source temperature: 600℃, spray voltage (ISVF) ±5500V (positive and negative modes); primary mass-to-charge ratio detection range: 60-1000Da, secondary product ion mass-to-charge ratio detection range: 25-1000Da, primary mass spectrometry scanning accumulation time: 0.20s / spectra, secondary mass spectrometry scanning accumulation time 0.05s / spectra; the secondary mass spectrum was obtained using the data-dependent acquisition mode (IDA), and the peak intensity value screening mode was adopted, declustering voltage (DP): ±60V (positive and negative modes), collision energy: 35±15eV, IDA settings are as follows: dynamic exclusion of isotope ion range: 4Da, 10 fragment spectra are collected for each scan.
[0097] Data analysis: The raw data were converted into .mzXML format by ProteoWizard, and then peak alignment, retention time correction and peak area extraction were performed using XCMS software. The data extracted by XCMS were first subjected to metabolite structure identification, data preprocessing (null value filtering: deleting ion peaks with missing values > 50%; null value filling: KNN filling: data filtering: filtering features with RSD > 50%), and then experimental data quality evaluation, and finally data analysis.
[0098] The overlap of the significantly different metabolites screened in each comparison group is displayed in the form of a venn diagram, which is helpful for screening the core metabolite modules related to biological processes; correlation analysis of differential metabolites can measure significant differences (VIP>1, p<0.05). KEGG pathway enrichment analysis is based on the KEGG pathway as a unit, with the metabolic pathways involved in the species or closely related species as the background, and the significance level of the metabolic pathway enrichment of each pathway is analyzed and calculated through Fisher's Exact Test.
[0099] like Fig. 9 As shown in the figure, there were 134 differential metabolites between the NCD group and the HFD group, 20 differential metabolites between the HFD group and HFD+CCP (3:2:2), and 13 common differential metabolites between the two groups. Fig.10 As shown in the figure, after a high-fat diet, the metabolites of Aspartic acid, L-Asparagine, L-Aspartate, L-Malic acid, L-Phenylalanine, L-Valine, Phenylalanine, D-glutamine, Glutamic acid, and Histidine increased in the mice in the HFD group. However, CCP (3:2:2) administration alleviated the increase of Aspartic acid, L-Asparagine, L-Aspartate, L-Malic acid, L-Phenylalanine, L-Valine, Phenylalanine, D-Glutamine, Glutamic acid, and Histidine. Fig.11 It can be seen that the enrichment of the Central carton metabolism in cancer pathway will cause the activation of the HIF-1α-NF-κB inflammatory pathway and aggravate atherosclerosis. The results showed that after the compound polysaccharide was administered, the atherosclerotic inflammation of mice was alleviated.
[0100] In summary, the formula of the present invention uses three kinds of edible fungi, and through careful processing and preparation, the best therapeutic effect of compound polysaccharide is exerted to treat atherosclerosis in a targeted manner. Compound polysaccharide can reduce the levels of TC, TG, and LDL-C in serum; relieve ApoE - / - Damage to major organs in mice with atherosclerosis; reduction of lipid droplet accumulation and vacuolization in adipose tissue and improvement of lipid metabolism; reduction of the proportion of white fat and increase of the proportion of brown fat; reduction of ApoE - / -Lipid accumulation in the aorta of atherosclerotic mice. At the same time, it can also alleviate the intestinal flora disorder of atherosclerotic mice and reduce the level of serum metabolites related to atherosclerosis. And the effect is better than that of a single polysaccharide.
[0101] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A compound polysaccharide, It is characterized in that The compound polysaccharide is prepared by using Tremella fuciformis, Agaricus bisporus and Boletus as raw materials through water extraction and alcohol precipitation. The weight ratio of Tremella fuciformis, Agaricus bisporus and Boletus is (1-5): (1-3): (1-3).
2. The compound polysaccharide according to claim 1, It is characterized in that The weight ratio of Tremella fuciformis, Agaricus bisporus and Boletus edulis is 3:2:
2.
3. The method for preparing the compound polysaccharide according to claim 1 or 2, It is characterized in that The following steps are involved: Washing, drying and crushing Tremella fuciformis, Agaricus bisporus and Boletus edulis respectively to obtain Tremella fuciformis powder, Agaricus bisporus powder and Boletus edulis powder; Mixing Tremella powder, Agaricus bisporus powder and Boletus powder according to a prescribed weight ratio; Take the mixed powder, add deionized water, extract twice, combine the extracts, and concentrate under reduced pressure to obtain a concentrate; The concentrated solution is dialyzed, ethanol is added after the dialysis, and the precipitate is collected by centrifugation. The precipitate is the compound polysaccharide.
4. The preparation method according to claim 3, It is characterized in that The volume ratio of the mixed powder to the deionized water is 1:
30.
5. The preparation method according to claim 3, It is characterized in that The extraction is performed at 80°C.
6. The preparation method according to claim 3, It is characterized in that The dialysis is performed by placing the precipitate under 3500Da conditions and dialyzing it at 4°C for 72 hours.
7. The preparation method according to claim 3, It is characterized in that The volume concentration of the ethanol is 95%; the volume ratio of the concentrated liquid to the ethanol is 1:5.
3.
8. Use of the compound polysaccharide according to claim 1 or 2 in the preparation of a drug for preventing and / or treating atherosclerosis.
9. The use according to claim 8, It is characterized in that The compound polysaccharide plays a role in preventing and / or treating atherosclerosis by reducing fat accumulation, lowering the contents of triglycerides, total cholesterol and low-density lipoprotein cholesterol in serum, improving intestinal flora disorders, improving lipid metabolism or lowering the levels of serum metabolites related to atherosclerosis.
10. A drug for preventing and treating atherosclerosis, It is characterized in that Contains the compound polysaccharide according to claim 1 or 2.
Citation Information
Patent Citations
Bolete extracting solution and beverages as well as preparation methods thereof
CN101715948A
Composite edible fungi polysaccharides and preparation method thereof
CN102093598A
Application of synanthrin to treatment of atherosclerosis and medicine containing synanthrin
CN115252639A
Agaricus bisporus polysaccharide extract as well as preparation method and application thereof
CN116789867A
Ganoderma lucidum exo- and endo-biopolymer having a hypolipidemic effect and the use thereof
KR1020040069423A
